CDK2 Monoclonal Antibody (2B6), Biotin | Invitrogen MA5-13476 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CDK2 Monoclonal Antibody (2B6), Biotin

catalog :

MA5-13476

quantity :

500µL

price :

US 425.00

clonality :

monoclonal

host :

mouse

conjugate :

biotin

clone name :

2B6

reactivity :

African green monkey, hamsters, human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section

citations: 24

Reference
Santaguida M, Nepveu A. Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1. J Biol Chem. 2005;280:32712-21 pubmed
Cameron R, Liu C, Mixon A, Pihkala J, Rahn R, Cameron P. Myosin16b: The COOH-tail region directs localization to the nucleus and overexpression delays S-phase progression. Cell Motil Cytoskeleton. 2007;64:19-48 pubmed
Hudson T, Hartle D, Hursting S, Nunez N, Wang T, Young H, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res. 2007;67:8396-405 pubmed
Wang Y, Wang X, Yang Z, Zhu G, Chen D, Meng Z. Menthol inhibits the proliferation and motility of prostate cancer DU145 cells. Pathol Oncol Res. 2012;18:903-10 pubmed
Haraguchi T, Koujin T, Osakada H, Kojidani T, Mori C, Masuda H, et al. Nuclear localization of barrier-to-autointegration factor is correlated with progression of S phase in human cells. J Cell Sci. 2007;120:1967-77 pubmed
Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle. 2007;6:1102-14 pubmed
Whittaker S, Walton M, Garrett M, Workman P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 2004;64:262-72 pubmed
Kutz H, Reisbach G, Schultheiss U, Kieser A. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology. 2008;371:246-56 pubmed
Sandal T, Stapnes C, Kleivdal H, Hedin L, Døskeland S. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells. J Biol Chem. 2002;277:20783-93 pubmed
Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90:5-14 pubmed
Yang X, Liu J, Ye L, Liao Q, Wu J, Gao J, et al. HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression. Virus Res. 2006;121:134-43 pubmed
Sansregret L, Goulet B, Harada R, Wilson B, Leduy L, Bertoglio J, et al. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol Cell Biol. 2006;26:2441-55 pubmed
Weroha S, Li S, Tawfik O, Li J. Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis. 2006;27:491-8 pubmed
Sáez A, Sáez A, Artiga M, Pérez-Rosado A, Camacho F, Diez A, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol. 2004;164:613-22 pubmed
Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828-37 pubmed
Raynaud F, Whittaker S, Fischer P, McClue S, Walton M, Barrie S, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res. 2005;11:4875-87 pubmed
Lai M, Chen T, Pang S, Yeh C. Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol. 2012;30:871-8 pubmed publisher
Garcia J, Camacho F, Morente M, Fraga M, Montalban C, Alvaro T, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-9 pubmed
Jirawatnotai S, Aziyu A, Osmundson E, Moons D, Zou X, Kineman R, et al. Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J Biol Chem. 2004;279:51100-6 pubmed
He D, Luo X, Wei W, Xie M, Wang W, Yu Z. DCPIB, a specific inhibitor of volume-regulated anion channels (VRACs), inhibits astrocyte proliferation and cell cycle progression via G1/S arrest. J Mol Neurosci. 2012;46:249-57 pubmed publisher
Santos C, Rodriguez-Pinilla M, Vega F, Rodriguez-Peralto J, Blanco S, Sevilla A, et al. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res. 2006;4:177-85 pubmed
Zhang Y, Xu P, Park K, Choi Y, Moore D, Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology. 2008;48:289-98 pubmed publisher
Hatjiharissi E, Ngo H, Leontovich A, Leleu X, Timm M, Melhem M, et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007;67:3777-84 pubmed
Yeh C, Lu S, Chao C, Chao M. Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun. 2003;305:311-4 pubmed

product information

Product Type :

Antibody

Product Name :

CDK2 Monoclonal Antibody (2B6), Biotin

Catalog # :

MA5-13476

Quantity :

500µL

Price :

US 425.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Human, Mouse, Rat

Applications :

Immunofluorescence: Assay Dependent, Immunohistochemistry (Paraffin): 1:25-50, Western Blot: 1-2 µg/ml

Species :

Human, Mouse, Rat

Clone :

2B6

Isotype :

IgG2b

Storage :

4° C

Description :

p33cdk2 associates with cyclin A in human cells. Kinase activity associated with cyclin A-cdc2 is found only in G2-phase. Cdk2 also complexes with cyclins E, D1, and D3. Cyclin E-cdk2 kinase is active in the G1- and S-phases of the cell cycle and is important (as does cyclin A-cdk2) for the progression from G1-to S-phase. The levels of cyclin A-cdk2 is maximal at the G1/S transition and both cdk2 and cyclin A are found associated with DNA in the initiation complex during replication. Rb protein acts as substrate for cdk2-cyclin E and/or cdk2-cyclin A in vivo. Cdk2 is activated and specifically localized to the nucleus during late G1-, S-, and G2-phase.

Immunogen :

Human recombinant cdk2 protein

Format :

Liquid

Applications w/Dilutions :

Immunofluorescence: Assay Dependent, Immunohistochemistry (Paraffin): 1:25-50, Western Blot: 1-2 µg/ml

Aliases :

cdc2-related protein kinase, cell devision kinase 2, cell division protein kinase 2, p33 protein kinase

PubMed References :

11909854, 12393683, 12745075, 14729633, 14742266, 15456744, 15770521, 16000586, 16081423, 16084954, 16311245, 16508018, 16547155, 16797769, 17029291, 17440091, 17457054, 17519288, 17804756, 17967471, 18537191, 21396835, 21559876, 22437241